STAT+: Sanofi, Regeneron expand partnership after Dupixent success — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sanofi is paying Regeneron $1 billion upfront to expand their antibody collaboration announced Thursday, with potential milestone payments of up to $7 billion more.
- Regeneron will lead research and development on the new pipeline while Sanofi takes the lead on commercialization, the same division of labor that produced blockbuster Dupixent.
- Profits on medicines emerging from the expanded collaboration will be split evenly between the two companies.
- George Yancopoulos, Regeneron's chief scientific officer, framed the deal as combining 'world-class scientific discovery and antibody development expertise' with Sanofi's 'global capabilities and reach.'
- The expanded collaboration targets immunological diseases—the same therapeutic area where their jointly developed Dupixent has already become a major commercial success.
Why it matters: The deal commits Sanofi to $1 billion upfront and up to $7 billion more in milestones, making it one of the larger re-up commitments between two pharma partners. The structure—Regeneron on R&D, Sanofi on commercialization, even profit split, immunology focus—directly mirrors the arrangement that built Dupixent into a blockbuster, betting the same playbook will deliver a sequel franchise.
Ask SkimNews
